Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BridgeBio Pharma, Inc.    BBIO

BRIDGEBIO PHARMA, INC.

(BBIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
68.61(c) 69.38(c) 67.71(c) 66.44(c) 69.48(c) Last
435 476 510 003 627 089 446 035 587 481 Volume
-1.61% +1.12% -2.41% -1.88% +4.58% Change
More quotes
Financials (USD)
Sales 2020 22,5 M - -
Net income 2020 -431 M - -
Net Debt 2020 24,8 M - -
P/E ratio 2020 -19,1x
Yield 2020 -
Sales 2021 79,8 M - -
Net income 2021 -443 M - -
Net Debt 2021 135 M - -
P/E ratio 2021 -20,5x
Yield 2021 -
Capitalization 8 516 M 8 516 M -
EV / Sales 2020 379x
EV / Sales 2021 108x
Nbr of Employees 369
Free-Float 56,4%
More Financials
Company
BridgeBio Pharma, Inc. is discovering and developing medicines that target well-characterized genetic diseases. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-265, BBP-831, BBP-631 and BBP-454. 
More about the company
Notations Surperformance© of BridgeBio Pharma, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about BRIDGEBIO PHARMA, INC.
01/20BRIDGEBIO PHARMA, INC. : Submission of Matters to a Vote of Security Holders, Ot..
AQ
01/20BRIDGEBIO PHARMA : Stockholders of BridgeBio Pharma Inc and Eidos Therapeutics I..
AQ
01/19Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve B..
GL
01/19miRagen Changes Name to Viridian; Names Jonathan Violin CEO, Barrett Katz Chi..
MT
01/13BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021..
GL
01/12BRIDGEBIO PHARMA, INC. : Other Events (form 8-K)
AQ
01/07BRIDGEBIO PHARMA : Director, Strategy & Transactions
PU
01/06BRIDGEBIO PHARMA : Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4..
AQ
01/05BRIDGEBIO PHARMA : Leading Independent Proxy Advisory Firm ISS Recommends Bridge..
AQ
01/04BRIDGEBIO PHARMA : Principal Accounting Officer Yi Ching Yau Steps Down
MT
01/04BRIDGEBIO PHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/04BRIDGEBIO PHARMA : Gets Proxy Advisory Firm Support For Merger With Eidos
MT
01/04Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and E..
GL
2020BRIDGEBIO PHARMA : UCSF Team Up to Accelerate Development of Therapeutics for Ge..
MT
2020UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therap..
GL
More news
News in other languages on BRIDGEBIO PHARMA, INC.

- No features available -

More news
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
More recommendations
Chart BRIDGEBIO PHARMA, INC.
Duration : Period :
BridgeBio Pharma, Inc. Technical Analysis Chart | BBIO | US10806X1028 | MarketScreener
Technical analysis trends BRIDGEBIO PHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 66,63 $
Last Close Price 69,48 $
Spread / Highest target 31,0%
Spread / Average Target -4,11%
Spread / Lowest Target -32,4%
EPS Revisions
Managers and Directors
NameTitle
Neil Kumar Chief Executive Officer & Director
Brian C. Stephenson Chief Financial Officer
Richard H. Scheller Director & Chairman-Research & Development
Charles J. Homcy Director & Chairman-Pharmaceuticals
Eric I. Aguiar Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRIDGEBIO PHARMA, INC.-2.29%8 516
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159